title: Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
abstract: OBJECTIVE
  A randomised, controlled clinical trial was initiated in 1984 to test whether 1 cycle of anthracycline-containing adjuvant chemotherapy improves the outcome of breast cancer patients presenting with stage II disease and negative oestrogen and progesterone receptors (ER, PgR), as compared with 6 cycles of dose-reduced CMF.
  
  
  METHODS
  Within 7 years 263 women with stage II breast cancer were randomised either to receive 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5- fluorouracil (AV-CMF) or to receive 6 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Patients were stratified for tumour stage, nodal stage, menopausal status, type of surgery and participating centre.
  
  
  RESULTS
  After a median follow-up of 100 months, neither disease-free (DFS) nor overall survival (OS) differed significantly between the two groups.
  
  
  CONCLUSIONS
  Compared to 6 cycles of a non-standard low-dose CMF regimen 1 cycle of anthracycline- containing adjuvant chemotherapy failed to improve the outcome in women with stage II receptor-negative breast cancer in terms of DFS and OS.
authors.affiliation: Klinische Abteilung für Onkologie, Medizinische Universitätsklinik, Karl-Franzens-Universität Graz. ferdinand.ploner@kfunigraz.ac.at
authors.forename: F
authors.initials: F
authors.lastname: Ploner
authors.forename: R
authors.initials: R
authors.lastname: Jakesz
authors.forename: H
authors.initials: H
authors.lastname: Hausmaninger
authors.forename: R
authors.initials: R
authors.lastname: Kolb
authors.forename: M
authors.initials: M
authors.lastname: Stierer
authors.forename: M
authors.initials: M
authors.lastname: Fridrik
authors.forename: P
authors.initials: P
authors.lastname: Steindorfer
authors.forename: M
authors.initials: M
authors.lastname: Gnant
authors.forename: K
authors.initials: K
authors.lastname: Haider
authors.forename: B
authors.initials: B
authors.lastname: Mlineritsch
authors.forename: G
authors.initials: G
authors.lastname: Tschurtschenthaler
authors.forename: G
authors.initials: G
authors.lastname: Steger
authors.forename: M
authors.initials: M
authors.lastname: Seifert
authors.forename: E
authors.initials: E
authors.lastname: Kubista
authors.forename: H
authors.initials: H
authors.lastname: Samonigg
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009367:Neoplasm Staging; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D015996:Survival Rate; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate